

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 April 2020 (02.04.2020)



(10) International Publication Number
WO 2020/065613 A1

(51) International Patent Classification:

A61K 31/437 (2006.01) C07D 498/04 (2006.01)
C07D 471/04 (2006.01) C07D 513/04 (2006.01)

(21) International Application Number:

PCT/IB2019/058240

(22) International Filing Date:

27 September 2019 (27.09.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/738,600 28 September 2018 (28.09.2018) US

(71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventor; and

(71) Applicant (for US only): AMERIKS, Michael K.
[US/US]; 3210 Merryfield Row, San Diego, California
92121 (US).

(72) Inventors: CHEN, Gang; 3210 Merryfield Row, San
Diego, California 92121 (US). HUANG, Chaofeng; 3210
Merryfield Row, San Diego, California 92121 (US).
LAFORTEZA, Brian Ngo; 3210 Merryfield Row, San
Diego, California 92121 (US). RAVULA, Suchitra; 3210
Merryfield Row, San Diego, California 92121 (US).
SOUTHGATE, Emma Helen; 3210 Merryfield Row, San
Diego, California 92121 (US). ZHANG, Wei; 3210 Merry-
field Row, San Diego, California 92121 (US).

(74) Agent: SHIRTZ, Joseph F. et al.; Johnson & Johnson,
One Johnson & Johnson Plaza, New Brunswick, New Jer-
sey 08933 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))


Published:

- with international search report (Art. 21(3))



WO 2020/065613 A1

(54) Title: MONOACYLGLYCEROL LIPASE MODULATORS



(57) Abstract: Fused compounds of Formula (I) and Formula (II), pharmaceuti-
cal compositions containing them, methods of making them, and methods of using
them including methods for treating disease states, disorders, and conditions asso-
ciated with MGL modulation, such as those associated with pain, psychiatric disor-
ders, neurological disorders (including, but not limited to major depressive disor-
der, treatment resistant depression, anxious depression, bipolar disorder), cancers
and eye conditions. and; Wherein R¹, R², R^{2a}, R³, R^{3a}, R⁴, and R^{4a} are defined
herein.